Table 3. Cycle characteristics of women in two groups undergoing IVF/ICSI treatment.

Characteristics	EMS group (n=150)	Tubal infertility group (n=150)	P
hMG dose, IU	1944.50±391.70	1961.00±304.30	0.684
hMG duration, days	8.86±1.53	8.89±1.19	0.866
hMG dose per follicle, IU	271.85±90.44	254.29±103.34	0.134
Cancelled cycle	0	0	–
Hyper-response, %	27.27 (33/121)	36.17 (51/141)	0.124
Poor-response, %	15.33 (23/150)	15 (18/120)	0.146
No. of >10 mm follicles on the triggering day	11.42±5.63	11.67±4.92	0.678
No. of >14 mm follicles on the triggering day	8.40±4.93	8.24±4.13	0.761
No. of oocytes retrieved	9.23±5.83	10.11±5.65	0.185
Mature oocyte rate, %	85.99 (1,191/1,385)	84.05 (1,275/1,517)	0.143
Fertilization rate, %	77.92 (928/1,191)	77.57 (989/1,275)	0.835
Cleavage rate, %	96.66 (897/928)	97.78 (968/989)	0.136
Viable embryo rate, %	33.50 (464/1,385)	34.87 (529/1,517)	0.437
High quality embryo rate, %	27.94 (387/1,385)	28.34 (430/1,517)	0.809
Blastulation rate, %	21.83 (112/513)	19.89 (109/548)	0.436
Cancellation rate, %	10.67 (16/150)	14 (21/150)	0.380
Immature oocyte rate, %	8.01 (111/1,385)	6.72 (102/1,517)	0.183

P: EMS group vs. control group. IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; EMS, endometriosis; MPA, medroxyprogesterone acetate; HMG, human menopausal gonadotropin.